Antisense Therapeutics financials at a glance

+ Portfolio

The revenue of Antisense Therapeutics is reported as 0.00196 billion Dollars in the fiscal year 2023. The earnings were -0.02 Dollars per share in 2023, which was 100 lower than 2022. And about -0.00818 billion Dollars are reported as free cash flow in the financials of Antisense Therapeutics 2023. No dividends were paid to the shareholders of the Antisense Therapeutics stock ASX:ANP in the financial year 2023.

$1.96M

Revenue

$-0.02

Earnings Per Share

97.91%

Gross Margin %

$-8.18M

Free Cash Flow

Revenue

1.96

Earnings Per Share

-0.02

Gross Margin %

97.91

Free Cash Flow

-8.18

Financials

Year	Year	TTM	2023	2022	2021	2020	2005	2004
Rev.	Revenue	N/A	$1.96M	$1.81M	$0.64M	$0.77M	$0.00M	$1.34M
GM %	Gross Margin %	97.91%	97.91%	96.31%	80.91%	69.51%	75.35%	91.43%
OM	Operating Margin	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
EPS	Earnings Per Share	$-0.02	$-0.02	$-0.01	$-0.01	$-0.01	$-0.18	$-0.14
Div.	Dividends	N/A	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
PR %	Payout Ratio %	0	-0.00%	-0.00%	-0.00%	0	-0.00%	-0.00%
Sha.	Shares	N/AM	836.3M	668.79M	574.48M	488.79M	35.53M	35.53M
OCF	Operating Cash Flow	N/A	$-8.15M	$-7.81M	$-5.83M	$0.00M	$0.00M	$0.00M
FCF	Free Cash Flow	N/A	$-8.18M	$-7.81M	$-5.84M	$0.00M	$0.00M	$0.00M
FCFS	Free Cash Flow Per Share	$-0.01	$-0.01	$-0.01	$-0.01	$-0.01	$-0.16	$-0.07

Antisense Therapeutics financials at a glance

Financials

Discover